Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
06 nov. 2024 07h30 HE
|
Arbutus Biopharma Corporation
Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase...
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
23 oct. 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
15 oct. 2024 08h16 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
01 oct. 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its...
Arbutus to Participate in Two Upcoming Investor Conferences
03 sept. 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
01 août 2024 07h30 HE
|
Arbutus Biopharma Corporation
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I...
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
18 juil. 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
06 juin 2024 11h15 HE
|
Arbutus Biopharma Corporation
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
05 juin 2024 02h30 HE
|
Arbutus Biopharma Corporation
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were...
Arbutus to Participate in Jefferies Global Healthcare Conference
29 mai 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...